

Appl. No. 09/927,006
Response. Dated December 22, 2004
Reply to Office Action of September 22, 2004

Amendments to the Claims:

This listing will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently amended): A purified peptide or its derivative having anti-angiogenic functionality of the structure:

Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp (hereinafter referred to as {4});

or

~~Trp-Pro-Gly-Asn-Ile-Asp-Gly-Asp-Pro-Asn-Arg (hereinafter referred to as {4'})~~;

or

~~Tyr-Thr-Met-Asn-Pro-Arg-Lys-Leu-Phe-Asp-Tyr (hereinafter referred to as {5})~~;

or

~~Tyr-Asp-Phe-Leu-Lys-Arg-Pro-Asn-Met-Thr-Tyr (hereinafter referred to as {5'})~~;

or

~~X-{4}-Y~~

or

~~X-{4'}-Y~~

or

Appl. No. 09/927,006
Response, Dated December 22, 2004
Reply to Office Action of September 22, 2004

~~X-{5}-Y~~

or

~~X-{5'}-Y~~

or

~~X-{4}-Ala-{5}-Y~~

or

~~X-{4'}-Ala-{5'}-Y~~

or

~~X-{5}-Ala-{4}-Y~~

or

~~X-{5'}-Ala-{4'}-Y~~

or

~~X-{4}-Cys-{5'}-Y~~

or

~~X-{4'}-Cys-{5'}-Y~~

or

~~X-{5}-Cys-{4}-Y~~

or

~~X-{5'}-Cys-{4'}-Y~~

or

Appl. No. 09/927,006

Response. Dated December 22, 2004

Reply to Office Action of September 22, 2004

~~X-{4}-(Gly-Gly-Gly-Ser)_n-{5}-Y~~

or

~~X-{4'}-(Gly-Gly-Gly-Ser)_n-{5'}-Y~~

or

~~X-{5}-(Gly-Gly-Gly-Ser)_n-{4}-Y~~

or

~~Cys-{4}-Ala-{5}-Cys~~

or

~~Cys-{4'}-Ala-{5'}-Cys~~

or

~~Cys-{5}-Ala-{4}-Cys~~

or

~~Cys-{5'}-Ala-{4'}-Cys~~

or

~~Ala-{4}-Ala-{5}-Ala~~

Appl. No. 09/927,006
Response. Dated December 22, 2004
Reply to Office Action of September 22, 2004

or

~~Ala {4'} Ala {5'} Ala~~

or

~~Ala {5} Ala {4} Ala~~

or

~~Ala {5'} Ala {4'} Ala~~

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein X is Acetyl group or other customary N-terminal protecting groups;

wherein y is amine, ethylamine, or other customary C-terminal protecting groups;

wherein n = 1 to 3; 3;

wherein the peptide sequence corresponds to the fourth peptide of peptides of GeneBank LocusID: 4018 which are separated by cysteine units.

Claim 2 (Currently amended): A pharmaceutical composition comprising ~~at least one of said peptides or peptide~~ or peptide derivative derivatives of claim 1.

Appl. No. 09/927,006
Response. Dated December 22, 2004
Reply to Office Action of September 22, 2004

Claim 3 (Currently amended): A purified peptide or its derivative according to claim 1, wherein at least one of amino acids of said peptide or derivative is in a D-form.

Claim 4 (Currently amended): A pharmaceutical composition comprising at least one of said peptide or peptide derivative ~~peptides or derivatives~~ of claim 3.

Claim 5 (Currently amended): A purified peptide or its derivative according to claim 1, wherein one amino acid is removed, replaced, or added to said peptide or derivative to form a new molecule.

Claim 6 (Currently amended): A pharmaceutical produce comprising at least one of said ~~peptides or derivatives~~ peptide or peptide derivative of claim 5.

Claim 7 (Currently amended): A purified peptide or its derivative according to claim 1, wherein either a C-terminal protecting group or an N-terminal protecting group is removed from the peptide ~~of~~ or derivative.

Claim 8 (Currently amended): A pharmaceutical product comprising at least one of said ~~peptides or derivatives~~ peptide or derivative of claim 7.

Claim 9-12 (Canceled)